Blog
RSS FeedPosted by Michael Wonder on 24 Aug 2016
NICE approves new cancer drugs for routine NHS use
24 August 2016 - Two cancer treatments, previously only available to patients through the Cancer Drugs Fund, will now be routinely ...
Posted by Michael Wonder on 23 Aug 2016
Rare blood cancer therapy Oncaspar gets NICE green light
23 August 2016 - Treatment from Baxalta/Shire for patients with acute lymphoblastic leukaemia recommended by NICE for use on the ...
Posted by Michael Wonder on 19 Aug 2016
NICE issues draft guidance on the first-line use of sorafenib tosylate (Nexavar) in advanced/metastatic hepatocellular carcinoma
19 August 2016 - The merits of Nexavar in liver cancer have been reviewed by NICE under the CDF rapid reconsideration ...
Posted by Michael Wonder on 18 Aug 2016
NICE recommends crizotinib, first pill for lung cancer
18 August 2016 - New draft guidance from NICE means hundreds of people will now have access to crizotinib, a twice-a-day ...
Posted by Michael Wonder on 12 Aug 2016
Thousands to benefit as NICE set to recommend drug to prevent heart attacks and strokes
12 August 2016 - NICE has published draft guidance recommending anti-clotting drug ticagrelor 60 mg with aspirin for people who have ...
Posted by Michael Wonder on 09 Aug 2016
NICE issues draft guidance on the use of talimogene laherparepvec
9 August 2016 - Talimogene laherparepvec (Imlygic) is the first cellular therapy to be appraised by NICE. ...
Posted by Michael Wonder on 04 Aug 2016
NICE issues draft guidance on the use of lesinurad
3 August 2016 - NICE has issued draft guidance on the use of lesinurad (Zurampic) for the treatment of patients ...
Posted by Michael Wonder on 04 Aug 2016
NICE draft guidance recommends new drug for people with ankylosing spondylitis
4 August 2016 - New draft guidance from NICE means thousands of people with back condition ankylosing spondylitis will soon have ...
Posted by Michael Wonder on 03 Aug 2016
NICE issues draft guidance on the use of Otezla (apremilast)
3 August 2016 - NICE has issued draft guidance on the use of apremilast for the treatment of patients with moderate ...
Posted by Michael Wonder on 27 Jul 2016
Vertex seeks deal after NICE rejects CF drug Orkambi
27 July 2016 - NICE has rejected Vertex’s cystic fibrosis drug, Orkambi (lumacaftor+ivacaftor) for routine funding on the National Health Service ...
Posted by Michael Wonder on 27 Jul 2016
Shire and BMS secure NICE recommendations for oncology drugs
27 July 2016 - NICE has issued final guidance recommending Shire’s Oncaspar (pegaspargase) and Bristol-Myers Squibb’s Opdivo (nivolumab) plus Yervoy (ipilimumab) ...
Posted by Michael Wonder on 27 Jul 2016
NICE publishes final guidance on the use of nivolumab in combination with ipilimumab for treating advanced melanoma
27 July 2016 - NICE publishes further guidance on the use of nivolumab (Opdivo) in patients wth melanoma. ...
Posted by Michael Wonder on 25 Jul 2016
NICE approves Servier’s Lonsurf as third-line cancer therapy
25 July 2016 - The National Institute for Health and Care Excellence has recommended trifluridine/tipiracil as an option for treating metastatic ...
Posted by Michael Wonder on 21 Jul 2016
Lilly’s Alimta wins NICE support
21 July 2016 - NHS use of Eli Lilly's Alimta to treat patients with lung cancer has been endorsed in final ...
Posted by Michael Wonder on 20 Jul 2016
NICE publishes final guidance recommending ataluren for children with Duchenne muscular dystrophy
20 July 2016 - NICE has published final guidance recommending ataluren for treating children aged 5 and over with Duchenne muscular ...